Araceli Biosciences added investor Jeff Swickard to its recently closed US$4.5 million financing round. The Tigard, Oregon, company makes high-performance cellular imaging systems for drug discovery. These tools support testing that relies less on animal models.
Funding use
The new capital will support efforts to use human cell science instead of animal testing. It will also help grow Oregon's technology and life sciences sector. Araceli expects 2026 revenue to be six times higher than two years earlier.
Company context
Araceli was founded in 2020 and became independent from Phoseon Technology in 2023. It employs roughly 30 people, with most based in Tigard. The company counts 10 of the world's top 20 pharmaceutical companies among its customers.
Product platform
The Endeavor platform lets researchers track how human cells react to drug compounds. Its AI analysis software serves pharmaceutical and biotechnology users across North America and Europe. The system makes New Approach Methodologies workable at scale.
Araceli is now moving into the second phase of its commercial strategy. It is introducing consumable products matched to its current instrument base. A wider launch is planned for 2027.